We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Siemens Enters Collaboration Agreement with Pfizer

By LabMedica International staff writers
Posted on 24 Dec 2013
Print article
Siemens Healthcare Diagnostics Inc. (Tarrytown, NY, USA) entered into a master collaboration agreement with Pfizer Inc. (New York, NY, USA) to design, develop, and commercialize diagnostic tests for therapeutic products across Pfizer's pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro companion diagnostics. The aim is eventual global commercialization with Pfizer products.

Companion diagnostic tests are clinical tests linked to a specific drug or therapy intended to help physicians make more correct personalized treatment decisions for patients. When used in the drug development process, companion diagnostics may help pharmaceutics companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.

The partnership will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care (POC) settings (including clinics and physician offices) to help enable diagnostics development.

"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," commented Dr. Trevor Hawkins, senior vice president, strategy & innovations, diagnostics division, Siemens Healthcare. John Hubbard, senior vice president and worldwide head of development operations at Pfizer emphasized that, "Companion diagnostics are an important enabler of targeted therapies for patients."

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a leader in medical imaging, laboratory diagnostics, medical information technology, and hearing aids. Siemens offers its customers products and solutions for patient care from a single source, from prevention and early detection, to diagnosis, and finally treatment and aftercare.

Related Links:

Siemens Healthcare Diagnostics Inc.
Pfizer Inc.


Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.